| Year | 2023 | 2022 |
|---|---|---|
| Total Revenue | 5.82B | 5.13B |
| Cost of Revenue | 1.94B | 1.71B |
| Gross Profit | 3.88B | 3.42B |
| Operating Expenses | 1.64B | 2.55B |
| Research and Development | 0 | 89.3M |
| Selling, General & Administrative Expenses | 1.54B | 537.9M |
| Selling & Marketing Expenses | 213M | 356.2M |
| General & Administrative Expenses | 1.33B | 181.7M |
| Other Expenses | 0 | 48M |
| Operating Income | 2.29B | 881M |
| Total Other Income/Expenses Net | -1.11B | -1.02B |
| Income Before Tax | 1.18B | 916.8M |
| Income Tax | 301.8M | 240.4M |
| Net Income | 876.6M | 676.4M |
| Basic EPS | 53 | 40.9 |
| EPS Diluted | 53 | 40.9 |
| Basic Average Shares | 16.54M | 16.54M |
| Diluted Average Shares | 16.54M | 16.54M |
| EBITDA | 1.36B | 1.08B |
RPG Life Sciences Limited
RPGLIFE.NS
NSE
1969.5INR-69.2 (-3.39%)
RPGLIFE.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 2.51B | 1.99B |
| Net Income | 876.6M | 676.4M |
| Stock Repurchases | 0 | 0 |
| Dividend Paid | -198.5M | -158.8M |
| Retained Earnings | 3.18B | 2.51B |
| Other Distributions | 474M | 359.5M |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 1.82B | 1.16B |
| Annual Depreciation | 170.7M | 155M |
| Capital Expenditure | -692.3M | -327.3M |
| Net PPE | 2.34B | 1.34B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 0 | 0 |
| Goodwill (Previous Year) | 0 | 0 |
| Goodwill | 0 | 0 |